Trial · NCT00936897
Adverse events152
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 152
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Ibandronate 150 mg PO QM | 9 | 410 | |
| other | Upper respiratory tract infection | Infections and infestations | Denosumab 60 mg SC Q6M | 21 | 411 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Ibandronate 150 mg PO QM | 23 | 410 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Denosumab 60 mg SC Q6M | 25 | 411 | |
| serious | Atrial fibrillation | Cardiac disorders | Ibandronate 150 mg PO QM | 0 | 410 | |
| serious | Atrial fibrillation | Cardiac disorders | Denosumab 60 mg SC Q6M | 2 | 411 | |
| serious | Atrioventricular block complete | Cardiac disorders | Ibandronate 150 mg PO QM | 1 | 410 | |
| serious | Atrioventricular block complete | Cardiac disorders | Denosumab 60 mg SC Q6M | 0 | 411 | |
| serious | Bradycardia | Cardiac disorders | Ibandronate 150 mg PO QM | 0 | 410 | |
| serious | Bradycardia | Cardiac disorders | Denosumab 60 mg SC Q6M | 2 | 411 | |
| serious | Cardiac failure congestive | Cardiac disorders | Ibandronate 150 mg PO QM | 0 | 410 | |
| serious | Cardiac failure congestive | Cardiac disorders | Denosumab 60 mg SC Q6M | 3 | 411 | |
| serious | Cardiac tamponade | Cardiac disorders | Ibandronate 150 mg PO QM | 1 | 410 | |
| serious | Cardiac tamponade | Cardiac disorders | Denosumab 60 mg SC Q6M | 0 | 411 | |
| serious | Coronary artery disease | Cardiac disorders | Ibandronate 150 mg PO QM | 1 | 410 | |
| serious | Coronary artery disease | Cardiac disorders | Denosumab 60 mg SC Q6M | 0 | 411 | |
| serious | Sick sinus syndrome | Cardiac disorders | Ibandronate 150 mg PO QM | 0 | 410 | |
| serious | Sick sinus syndrome | Cardiac disorders | Denosumab 60 mg SC Q6M | 2 | 411 | |
| serious | Wolff-Parkinson-White syndrome | Cardiac disorders | Ibandronate 150 mg PO QM | 1 | 410 | |
| serious | Wolff-Parkinson-White syndrome | Cardiac disorders | Denosumab 60 mg SC Q6M | 0 | 411 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00936897/events